Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A fluorescence in situ hybridisation (FISH) assay has been used to screen for ETV1 gene rearrangements in a cohort of 429 prostate cancers from patients who had been diagnosed by trans-urethral resection of the prostate. The presence of ETV1 gene alterations (found in 23 cases, 5.4%) was correlated with higher Gleason Score (P=0.001), PSA level at diagnosis (P=<0.0001) and clinical stage (P=0.017) but was not linked to poorer survival. We found that the six previously characterised translocation partners of ETV1 only accounted for 34% of ETV1 re-arrangements (eight out of 23) in this series, with fusion to the androgen-repressed gene C15orf21 representing the commonest event (four out of 23). In 5'-RACE experiments on RNA extracted from formalin-fixed tissue we identified the androgen-upregulated gene ACSL3 as a new 5'-translocation partner of ETV1. These studies report a novel fusion partner for ETV1 and highlight the considerable heterogeneity of ETV1 gene rearrangements in human prostate cancer.

Original publication

DOI

10.1038/sj.bjc.6604472

Type

Journal article

Journal

Br J Cancer

Publication Date

22/07/2008

Volume

99

Pages

314 - 320

Keywords

Coenzyme A Ligases, Cohort Studies, DNA-Binding Proteins, Gene Fusion, Gene Rearrangement, Genetic Heterogeneity, Humans, In Situ Hybridization, Fluorescence, Male, Paraffin Embedding, Prostatic Neoplasms, Reverse Transcriptase Polymerase Chain Reaction, Transcription Factors, Translocation, Genetic